Angiotensin converting enzyme inhibitors in the prevention of diabetic renal disease

Current Opinion in Endocrinology and Diabetes

Volumn 4, Issue 1, 1997, Pages 10-15

  Williams, Mark E ^a  

^a JOSLIN DIABETES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001240596     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-199702000-00002     Document Type: Article

References (62)

1. Morgensen CE: Nature of microalbuminuria, proteinuria, and progressive renal disease. J Diabetes Complications 1995, 9:2-6.
2. Rossing P, Rossing K, Jacobsen P, Parving HH: Unchanged incidence of diabetic nephropathy in IDDM patients. Diabetes 1995, 44:739-743.
3. Lloyd CE, Orchard TJ: Diabetes complications: the renal-retinal link. Diabetes Care 1995, 18:1034-1036.
4. Anderson S, Meyer TW, Rennke HG, Brenner BM: Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 1985, 76:612-619.
5. Maschio G, Alberti D, Janin G, Locatelli F, Mann JFE, Motolese M, Ponticelli C, Ritz E, Zucchelli P: Effect of the angiotensin-converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996, 334:939-945.
6. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993, 329:1456-1462.
7. Liou HH, Huang TP, Campese VM: Effect of long-term therapy with captopril on proteinuria and renal function in patients with non-insulin dependent diabetes and with non-diabetic renal diseases. Nephron 1995, 69:41-48.
8. Ravid M, Lang R, Rachmani R, Lishner M: Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus: a 7-year follow-up study. Arch Intern Med 1996, 156:286-289.
9. Parving HH, Rossing P, Hommel E, Smidt UM: Angiotensin-converting enzyme inhibition in diabetic nephropathy: ten years' experience. Am J Kidney Dis 1995, 26:99-107. Largest available follow-up study of the effects of ACE inhibitors on diabetic nephropathy.
10. Dunfee T: The changing management of diabetic nephropathy. Hosp Practice May 15, 1995, 45-55.
11. Klein R, Klein BEK, Moss SE, Cruickshanks KJ: Ten-year incidence of gross proteinuria in people with diabetes. Diabetes 1995, 44:916-923.
12. Pedrini MT, Levey AS, Lau J, Chalmers TC: The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis. Ann Intern Med 1996, 124:627-632.
13. Komers R, Cooper ME: Acute renal hemodynamic effects of ACE inhibition in diabetic hyperfiltration: role of kinins. Am J Physiol 1995, 268:F588-F594.
14. Dzau VJ: Tissue angiotensin system in cardiovascular medicine. A paradigm shift? Circulation 1994, 89:493-498.
15. Hollenberg NK, Fischer NDL: Renal circulation and blockade of the renin-angiotensin system. Is angiotensin-converting enzyme inhibition the last word? Hypertension 1995, 26:602-609. Comprehensive review of ACE inhibition.
16. Bianchi C, Gutkowska J, Thibault G, Garcia R, Genest J, Cantin M: Distinct localization of atrial natriuretic factor and angiotensin II binding sites in the glomerulus. Am J Physiol 1986, 251:F594-F602.
17. Anderson S, Jung FF, Ingelfinger JR: Renal renin-angiotensin system in diabetes: functional, immunohistochemlcal, and molecular biological correlations. Am J Physiol 1993, 265:F477-F486.
18. Harris RC, Inagami T: Molecular biology and pharmacology of angiotensin receptor subtypes. In Hypertension, Physiology, Diagnosis and Management, edn 2. Edited by Laragh JH, Brenner BM. New York: Raven Press; 1995:1721-1738.
19. Weir NM: Angiotensin-II receptor antagonists: a new class of antihypertensive agents. Am Fam Physician 1996, 53:589-594.
20. Mackenzie HS, Troy JL, Rennke HG, Brenner BM: TCV 116 prevants progressive renal injury in rats with extensive renal mass ablation. J Hypertens 1994, 12(suppl 9):S11-S16.
21. Vranes D, Cooper ME, Dilley RJ: Angiotensin-converting enzyme inhibition reduces diabetes-induced vascular hypertrophy: morphometric studies. J Vasc Res 1995, 32:183-189.
22. Janderleit K, Rumble J, Jackson B, Cooper M: Mesenteric vascular angiotensin-converting enzyme is increased in experimental diabetes mellitus. Clin Exp Pharmacol Physiol 1992, 19:343-347.
23. Sharma K, Ziyadeh FN: Perspectives in diabetes: hyperglycemia and diabetic kidney disease, the case for transforming growth factor-β as a key mediator. Diabetes 1995, 44:1139-1146.
24. Tooke JE: Perspectives in diabetes: microvascular function in human diabetes, a physiological perspective. Diabetes 1995, 44:721-726. Analyzes microvascular dysfunction in diabetes.
25. Feldt-Rasmussen B, Mathiesen ER, Deckert T, et al.: Central role for sodium in the pathogenesis of blood pressure changes independent of angiotensin, aldosterone and catecholamines in type I (insulin-dependent) diabetes mellitus. Diabetologia 1987, 30:610-617.
26. Matinlauri IH, Ronnemaa T, Koskinen PJ, Aalto MA, Viikari JSA, Irjala KMA: Elevated serum total renin is insensitive in detecting incipient diabetic nephropathy. Diabetes Care 1995, 18:1357-1361.
27. Krolewski AS, Warram JH: Epidemiology of late complications of diabetes. In Joslin's Diabetes Mellitus, edn 13. Edited by Kahn CR, Weir GC. Philadelphia: Lea & Febiger, 1994:605-619.
28. Quinn M, Angelico MC, Warram JH, Krolewski AS: Familial factors determine the development of diabetic nephropathy in patients with IDDM. Diabetologia 1996, 39:940-945.
29. Mangili R, Bending JJ, Scott G, Li LK, Gupta A, Viberti GC: Increased sodium-lithium countertransport activity in red cells of patients with insulin-dependent diabetes and nephropathy. N Engl J Med 1988, 318:146-50.
30. Marre M, Bernadet P, Gallois Y, Savagner F, Guyane TT, Hallab M, Cambien F, Passa P, Alhenc-Gelas F: Relationships between angiotensin I converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications. Diabetes 1994, 43:384-388.
31. Nagi DK, Mansfield MW, Stickland MH, Grant PJ: Angiotensin converting enzyme (ACE) insertion/deletion (I/D) polymorphism, and diabetic retinopathy in subjects with IDDM and NIDDM. Diabetic Med 1995, 12:997-1001.
32. Chowdhury TA, Dronsfield MJ, Kumar S, Gough SLC, Gibson SP, Khatoon A, MacDonald F, Rowe BR, Dunger DB, Dean JD, Daview SJ, Webber J, Smith PR, Mackin P, Marshall SM, Adu D, Morris PJM, Todd JA, Barnett AH, Boulton AJM, Bain SC: Examination of two genetic polymorphisms within the renin-angiotensin system: no evidence for an association with nephropathy in IDDM. Diabetologia 1996, 39:1108-1114.
33. Doria A, Warram JH, Krolewski AS: Genetic predisposition to diabetic nephropathy. Evidence for a role of the angiotensin I-converting enzyme gene. Diabetes 1994, 43:690-695.
34. Raynolds WV, Bristow NM, Bush EW, Abraham WT, Lowes BD, Zisman LS, Taft CS, Perryman MB: Angiotensin-converting enzyme DD genotype in patients with ischaemic or idiopathic dilated cardiomyopathy. Lancet 1993, 342:1073-1075.
35. van Essen GG, Rensma PL, de Zeeuw D, Sluiter WJ, Scheffer H, Apperloo AJ: Association between angiotensin-converting-enzyme gene polymorphism and failure of renoprotective therapy. Lancet 1996, 347:91-95.
36. Keilani T, Schlueter W, Batlle D: Selected aspects of ACE inhibitor therapy for patients with renal disease: impact on proteinuria, lipids and potassium. J Clin Pharmacol 1995, 35:87-97. Discusses metabolic consequences of ACE inhibitors.
37. Manto A, Cotroneo P, Marra G, Magnani P, Tilli P, Greco AV, Ghirlanda G: Effect of intensive treatment on diabetic nephropathy in patients with type I diabetes. Kidney Int 1995, 47:231-235.
38. Consensus Statement: Treatment of hypertension in diabetes. Diabetes Care 1996, 19(suppl 1):5107-5113. Current recommendations for the hypertensive diabetic.
39. Falkner B, Canessa M, Anzalone D: Effect of angiotensin converting enzyme inhibitor (lisinopril) on insulin sensitivity and sodium transport in mild hypertension. Am J Hypertens 1995, 8:454-460.
40. Pollare T, Lithell H, Berne C: A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989, 321:868-873.
41. Herings RMC, de Boer A, Stricker BHC, Leufkens HGM, Porsius A: Hypoglycemia associated with use of inhibitors of angiotensin converting enzyme. Lancet 1995, 345:1195-1198.
42. Leighton B, Sanderson AL, Young ME, Radda GK, Boehm EA, Clark JF: Effects of treatment of spontaneously hypertensive rats with the angiotensin-converting enzyme inhibitor trandolapril and the calcium antagonist verapamil on the sensitivity of glucose metabolism to insulin in rat soleus muscle in vitro. Diabetes 1995, 45(suppl 1):S120-S124.
43. Hoenack C, Roesen P: Inhibition of angiotensin type I receptor prevents decline of glucose transporter (GLUT4) in diabetic rat heart. Diabetes 1996, 45(suppl 1):S82-S87.
44. Shield JPH, Hunt LP, Karachaliou F, Karavanaki K, Baum JD: Is microalbuminuria progressive? Arch Dis Child 1995, 73:512-514.
45. Mogensen CE, Keane WF, Bennett PH, Jerums G, Parving HH, Passa P, Steffes MW, Striker GE, Viberti GC: Prevention of diabetic renal disease with special reference to microalbumin. Lancet 1995, 346:1080-1084.
46. Mogensen CE: Management of early nephropathy in diabetic patients. Annu Rev Med 1995, 46:79-94. Review article including ACE inhibitors.
47. Bennett PH, Haffner S, Kasiske BL, Keane WF, Mogensen CE, Parving HH, Steffes MW, Striker GE: Screening and management of microalbuminuria in patients with diabetes mellitus: recommendations to the Scientific Advisory Board of the National Kidney Foundation from an Ad Hoc Committee of the Council on Diabetes Mellitus of the National Kidney Foundation. Am J Kidney Dis 1995, 25:107-112.
48. Laffel LMB, McGill JB, Gans DJ: The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. Am J Med 1995, 99:497. Reports on the use of ACE inhibitors for the treatment of preclinical nephropathy.
49. Sassy-Prigent C, Heudes D, Jouquey S, Auberval D, Belair MF, Michel O, Hamon G, Bariety J, Bruneval P: Morphometric detection of incipient glomerular lesions in diabetic nephropathy in rats. Lab Invest 1995, 73:64.
50. Inserra F, Daccordi H, Ippolito JL, Romano L, Zelechower H, Ferder L: Decrease of exercise-induced microalbuminuria in patients with type I diabetes by means of an angiotensin-converting enzyme inhibitor. Am J Kidney Dis 1996, 27:26-33.
51. Frampton JE, Peters DH: Ramipril: an updated review of its therapeutic use in essential hypertension and heart failure. Drugs 1995, 3:440-466.
52. Maki DD, Ma JZ, Louis TA, Kasiske BL: Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med 1995, 155:1073-1080.
53. Campbell DJ, Lawrence AC, Towrie A, Kladis A, Valentijn AJ: Differential regulation of angiotensin peptide levels in plasma and kidney of the rat Hypertension 1991, 18:763-773.
54. Gansevoort RT, de Zeeuw D, de Jong PE: Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int 1994, 45:861-867. Explores the mechanisms of the effects of ACE inhibitors.
55. Remuzzi A, Benigni A, Malanchini B, Bruzzi I, Foglieni C, Remuzzi G: ACE inhibition prevents renal failure and death in uninephrectomized MWF/Ztm rats. Kidney Int 1995, 47:1319-1326.
56. Volpert OV, Ward WF, Lingen MW, Chester L, Solt DB, Johnson MD, Molteni A, Polverini PJ, Bouck NP: Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 1996, 98:671-679.
57. Hansen PM, Mathiesen ER, Enevoldsen AK, Deckert T: Possible effect of angiotensin-converting enzyme inhibition on glomerular charge selectivity. J Diabetes Complications 1995, 3:158-162.
58. Rodby RA, Firth LM, Lewis EJ: An economic analysis of captopril in the treatment of diabetic nephropathy. Diabetes Care 1996, 19:1051-1061.
59. Kiberd BA, Jindal K: Screening to prevent renal failure in insulin dependent diabetic patients: an economic evaluation. BMJ 1995, 311:1595-1599.
60. Anderson S, Ingelfinger JR: Chronic angiotensin II receptor blockade lowers arterial pressure and glomerular capillary pressure in diabetic rats [abstract]. Am J Hypertens 1991, 4:12a.
61. Rhaleb NE, Rouissi N, Nantel F, D'Orleans JP, Regoli D: Dup 753 is a specific antagonist for the angiotensin receptor. Hypertension 1991, 17:480-484.
62. Goldberg AI, Dunlay MC, Sweet CS: Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol 1995, 75:793-795.